SPY765.80+0.02%QQQ737.05+0.07%BTC/USD83,083.00−0.45%DIA514.14+0.02%GLD378.31+0.11%TLT78.69+0.09%
Benzinga

Biotech

AbbVie’s New Parkinson’s Pill Could Become a Billion-Dollar Drug, Analyst Says
AbbVie’s New Parkinson’s Pill Could Become a Billion-Dollar Drug, Analyst Says
Zymeworks Updates Annual Financial Targets After Finalizing Theravance Biopharma Deal
Zymeworks Updates Annual Financial Targets After Finalizing Theravance Biopharma Deal
Regeneron Eylea Feels the Pinch as Kodiak Advances Extended Dosing for Eye Drug
Regeneron Eylea Feels the Pinch as Kodiak Advances Extended Dosing for Eye Drug
Zymeworks Updates Annual Financial Targets After Finalizing Theravance Biopharma Deal
Zymeworks Updates Annual Financial Targets After Finalizing Theravance Biopharma Deal
Regeneron Eylea Feels the Pinch as Kodiak Advances Extended Dosing for Eye Drug
Regeneron Eylea Feels the Pinch as Kodiak Advances Extended Dosing for Eye Drug
MediciNova Drug Falls Short on Liver Fat Parameter, Stock Tumbles
MediciNova Drug Falls Short on Liver Fat Parameter, Stock Tumbles
Kodiak Sciences Says Eye Drug on Par with Regeneron's Medicine
Kodiak Sciences Says Eye Drug on Par with Regeneron's Medicine

Biotech Recent News

Merck, Daiichi Sankyo Scrap FDA Application for Lung Cancer Drug
Merck, Daiichi Sankyo Scrap FDA Application for Lung Cancer Drug
Merck and Daiichi Sankyo voluntarily withdrew their FDA application for a lung cancer drug due to insufficient data, though trials continue.
'We Don't Know What the Risks Are': GLP-1 Pill Boom Fuels Hundreds of Apps, but Research Is Lagging
'We Don't Know What the Risks Are': GLP-1 Pill Boom Fuels Hundreds of Apps, but Research Is Lagging
Oral GLP-1 weight-loss pills are driving a health-tech boom, but research on their safe use is struggling to keep pace.
What's Going on With Novo Nordisk Stock on Friday?
What's Going on With Novo Nordisk Stock on Friday?
Novo Nordisk eyes M&A to counter patent cliff risks, and partners with Nanexa for long-acting injectables.
Firefly Neuroscience and Neurosigma Partner To Expand Non-Drug Pediatric ADHD Care
Firefly Neuroscience and Neurosigma Partner To Expand Non-Drug Pediatric ADHD Care
Firefly Neuroscience partners with NeuroSigma to expand access to the FDA-cleared Monarch eTNS non-drug ADHD treatment nationwide.
Johnson & Johnson Clinical Trials Show Progress Across Key Therapies
Johnson & Johnson Clinical Trials Show Progress Across Key Therapies
Johnson & Johnson shares key clinical trial results for Tremfya in psoriatic arthritis and five-year Carvykti data in multiple myeloma.
Eli Lilly Did Breach Implied Covenant of Good Faith With Nektar Therapeutics, Jury Funds
Eli Lilly Did Breach Implied Covenant of Good Faith With Nektar Therapeutics, Jury Funds
Nektar Therapeutics wins $90 million jury verdict against Eli Lilly in lawsuit over their rezpegaldesleukin licensing agreement.
Why is Moderna (MRNA) Stock Trending After Hours?
Why is Moderna (MRNA) Stock Trending After Hours?
Moderna shares rose 0.09% after hours Thursday as investors eyed upcoming oncology data at a major European conference.
Why Is Arcturus Therapeutics Stock Gaining Thursday?
Why Is Arcturus Therapeutics Stock Gaining Thursday?
Arcturus Therapeutics (ARCT) surged over 6% after sharing positive Phase 2 interim data for its OTC deficiency drug, ARCT-810.
Acadia Drug Misses Primary Goal in Alzheimer’s Related Psychosis
Acadia Drug Misses Primary Goal in Alzheimer’s Related Psychosis
Acadia Pharmaceuticals reports Phase 2 remlifanserin trial results for Alzheimer’s psychosis and plans to move into Phase 3.
Positive FDA Alignment Boosts ATyr Pharma's Rare Lung Disease
Positive FDA Alignment Boosts ATyr Pharma's Rare Lung Disease
aTyr Pharma reached FDA alignment on a Phase 3 study for efzofitimod to treat pulmonary sarcoidosis, beginning in Q4 2026.
Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved